BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+7.64%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.56B
AUM Growth
+$19.4M
(+0.3%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-3.59%
Top 10 Holdings %
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14
Top Buys
| 1 |
DexCom
DXCM
|
$42.5M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$17.8M |
| 3 |
SI-BONE Inc
SIBN
|
$16.6M |
| 4 |
Steris
STE
|
$16.5M |
| 5 |
Beam Therapeutics
BEAM
|
$16.5M |
Top Sells
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$114M |
| 2 |
Intuitive Surgical
ISRG
|
$59.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$51.7M |
| 4 |
Evolent Health
EVH
|
$29.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$28.3M |
Sector Composition
| 1 | Healthcare | 99.12% |
| 2 | Industrials | 0.77% |
| 3 | Technology | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Xenon Pharmaceuticals
XENE
$2.96B
| $607K | 0.01% |
14,100
-7,900
| -36% | -$340K |
|
127
Protagonist Therapeutics
PTGX
$3.61B
| $554K | 0.01% |
19,146
-10,854
| -36% | -$314K |
|
128
Rhythm Pharmaceuticals
RYTM
$6.85B
| $542K | 0.01% |
12,500
-20,369
| -62% | -$883K |
|
129
Rocket Pharmaceuticals
RCKT
$342M
| $531K | 0.01% |
19,700
-1,300
| -6% | -$35K |
|
130
4D Molecular Therapeutics
FDMT
$286M
| $500K | 0.01% |
+15,700
| New | +$500K |
|
|
BPMC
131
DELISTED
Blueprint Medicines
BPMC
| $484K | 0.01% |
+5,100
| New | +$484K |
|
132
C4 Therapeutics
CCCC
$184M
| $471K | 0.01% |
57,600
-4,400
| -7% | -$35.9K |
|
133
Tenet Healthcare
THC
$16.9B
| $446K | 0.01% |
4,244
+2,797
| +193% | +$294K |
|
134
Viking Therapeutics
VKTX
$2.93B
| $443K | 0.01% |
5,400
-12,100
| -69% | -$992K |
|
135
Merus
MRUS
$4.9B
| $441K | 0.01% |
9,800
-12,900
| -57% | -$581K |
|
136
Astrana Health
ASTH
$1.42B
| $431K | 0.01% |
+10,256
| New | +$431K |
|
137
Garmin
GRMN
$45.8B
| $417K | 0.01% |
+2,800
| New | +$417K |
|
138
BridgeBio Pharma
BBIO
$9.8B
| $396K | 0.01% |
12,800
-20,500
| -62% | -$634K |
|
|
VERV
139
DELISTED
Verve Therapeutics
VERV
| $388K | 0.01% |
29,200
-9,800
| -25% | -$130K |
|
140
Apple
AAPL
$3.53T
| $377K | 0.01% |
+2,200
| New | +$377K |
|
141
West Pharmaceutical
WST
$17.9B
| $344K | 0.01% |
+870
| New | +$344K |
|
142
Dynavax Technologies
DVAX
$1.18B
| $342K | 0.01% |
27,558
-15,642
| -36% | -$194K |
|
143
Cardinal Health
CAH
$35.6B
| $336K | 0.01% |
3,000
-500
| -14% | -$56K |
|
144
Viridian Therapeutics
VRDN
$1.5B
| $334K | 0.01% |
19,100
-10,900
| -36% | -$191K |
|
|
BCYC
145
Bicycle Therapeutics
BCYC
$469M
| $311K | ﹤0.01% |
12,500
-7,500
| -38% | -$187K |
|
146
Madrigal Pharmaceuticals
MDGL
$9.56B
| $283K | ﹤0.01% |
+1,060
| New | +$283K |
|
147
Amneal Pharmaceuticals
AMRX
$2.94B
| $275K | ﹤0.01% |
45,387
+19,917
| +78% | +$121K |
|
148
ADMA Biologics
ADMA
$3.99B
| $270K | ﹤0.01% |
+40,900
| New | +$270K |
|
149
Simply Good Foods
SMPL
$2.87B
| $269K | ﹤0.01% |
+7,900
| New | +$269K |
|
150
Biomea Fusion
BMEA
$107M
| $266K | ﹤0.01% |
17,800
-7,200
| -29% | -$108K |
|